🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma NCT07121946Phase 16 sites📍 Duarte📍 St Louis📍 Buffalo LTZ Therapeutics, Inc. · Tests: LTZ-301, LTZ-301, LTZ-301 Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT03936153Phase 223 sites📍 Beijing📍 Beijing📍 Beijing Xynomic Pharmaceuticals, Inc. · Tests: abexinostat SynKIR-310 for Relapsed/Refractory B-NHL NCT06544265Phase 15 sites📍 Denver📍 Atlanta📍 Fairway Verismo Therapeutics · Tests: SynKIR-310 Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06015880Phase 18 sites📍 Duarte📍 Sacramento📍 Tampa National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Lenalidomide, Mosunetuzumab, Polatuzumab Vedotin Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL NCT05552937Phase 21 site📍 Hangzhou Beijing InnoCare Pharma Tech Co., Ltd. · Tests: Tafasitamab and Lenalidomide A Study of Ultra-fraction Radiotherapy Bridging CART in R/R DLBCL NCT05514327NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: ultra-fraction radiotherapy Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site📍 Milan Incyte Biosciences Italy S.r.l Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) NCT07197307Phase 234 sites📍 Aachen📍 Augsburg📍 Berlin Universität Münster · Tests: Loncastuximab Tesirine and Epcoritamab A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies NCT06528301Phase 19 sites📍 Duarte📍 Chicago📍 Grand Rapids Umoja Biopharma · Tests: UB-VV111, rapamycin Low Dose Epcoritamab Plus GemOx in R/R DLBCL NCT07451652Phase 21 site📍 Monterrey Hospital Universitario Dr. Jose E. Gonzalez · Tests: Epcoritamab, Gemcitabine (1000 mg/m2), Oxaliplatin A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies NCT07735533Phase 1, Phase 21 site📍 Nashville Umoja Biopharma · Tests: UB-VV400, Rapamycin (sirolimus) A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites📍 Gilbert📍 Scottsdale📍 Scottsdale Lyell Immunopharma, Inc. · Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma NCT07189065Phase 241 sites📍 Hefei📍 Beijing📍 Beijing Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Rocbrutinib, Bendamustine, Rituximab, Lenalidomide KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT07260812Phase 11 site📍 Wuhan TCRx Therapeutics Co.Ltd · Tests: KSV01 Injection Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites📍 Tucson📍 Tucson📍 Los Angeles National Cancer Institute (NCI) · Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden NCT06867536Phase 21 site📍 Wuhan Liling Zhang · Tests: Glofitamab + Obinutuzumab Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma NCT07126236Phase 219 sites📍 Seville📍 Zaragoza📍 Palma de Mallorca Grupo Español de Linfomas y Transplante Autólogo de Médula … · Tests: Epcoritamab, Epcoritamab, tafasitamab and lenalidomide A Study of APG-3288 in Relapsed/Refractory Blood Cancers NCT07424833Phase 16 sites📍 Los Angeles📍 Jacksonville📍 Grand Rapids Ascentage Pharma Group Inc. · Tests: APG-3288 A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL NCT06086197Phase 21 site📍 Hangzhou Zhejiang Cancer Hospital · Tests: Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma NCT07570017Phase 12 sites📍 Guangzhou📍 Shanghai Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Rocbrutinib, R-GemOx Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy NCT06854159Phase 21 site📍 Sacramento University of California, Davis · Tests: Chimeric Antigen Receptor T-Cell Therapy, Odronextamab NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118Phase 2, Phase 34 sites📍 Ankara📍 Ankara📍 Ankara Health Institutes of Turkey · Tests: Talikabtagene Autoleucel A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) NCT05139017Phase 2, Phase 3135 sites📍 Glendale📍 Beverly Hills📍 Walnut Creek Merck Sharp & Dohme LLC · Tests: Zilovertamab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Bendamustine DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT04920617Phase 250 sites📍 Fountain Valley📍 Boca Raton📍 Hollywood ImmunoVaccine Technologies, Inc. (IMV Inc.) · Tests: DPX-Survivac, Pembrolizumab, CPA Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma NCT06464861Phase 11 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: CD19-CAR-NK/T Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma NCT05272384Phase 19 sites📍 Birmingham📍 Duarte📍 Sacramento National Cancer Institute (NCI) · Tests: Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Nivolumab, Positron Emission Tomography A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma NCT07062627Phase 21 site📍 Seoul Hyungwoo Cho · Tests: Anbal-cel A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies NCT05131022Phase 162 sites📍 Duarte📍 San Francisco📍 Denver Nurix Therapeutics, Inc. · Tests: NX-5948 Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma NCT06830031Phase 11 site📍 Tianjin Shanghai Exuma Biotechnology Ltd. · Tests: C402-CD19-CAR
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy